(English) ANA Therapeutics Announces U.S. FDA Clearance Of IND Application To Initiate Clinical Trial Of Niclosamide In COVID-19 Patients

FOSTER CITY, Calif., Aug. 4, 2020 /PRNewswire/ — ANA Therapeutics (ANA), a Silicon Valley-based biotech start-up announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ANA001 (niclosamide capsules) as a potential treatment for COVID-19, making it the first U.S.-based company to conduct a human clinical trial to determine the efficacy of niclosamide to treat COVID-19.

ANA Therapeutics clinical trial will seek to enroll at…